Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial
Randomised controlled trialHumans
- Design
- Randomised controlled trial
- Subjects
- 60 patients with schizophrenia randomised. 50 completed, 25 in each group.
- Dose used in the study
- 600 mg twice a day, added to a stable dose of the antipsychotic risperidone. The comparison group took placebo with risperidone.
- Duration
- 8 weeks
- What was measured
- Negative symptoms on the PANSS scale as the main outcome, plus positive symptoms, depressive symptoms and movement side effects
What the authors reported
Negative symptoms improved more in the palmitoylethanolamide group (p = 0.012). Positive symptoms and depressive symptoms did not differ between the groups. Adverse events and movement side effects did not differ.
Limits of this study
All patients also took risperidone, so the trial tested palmitoylethanolamide as an add-on. Ten of the 60 patients did not complete. The trial ran for 8 weeks. Limitations were not visible on the page checked. It was funded by a grant from Tehran University of Medical Sciences.
Source
doi:10.1016/j.psychres.2022.114737
Entry checked against the abstract page at the publisher (ScienceDirect) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.